Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESSO 45 | Building melanoma tissue repositories for personalized vaccine therapy

Roger Olofsson Bagge, MD, PhD, Gothenburg University, Gothenburg, Sweden, highlights the importance of building tissue repositories from primary melanoma specimens to enable future personalized vaccine treatment for patients at high risk of recurrence or requiring adjuvant therapy. Surgeons remain essential members of the multidisciplinary team in establishing these infrastructure systems and challenges remain in translating new vaccine approaches from controlled clinical trials into real-world clinical practice across diverse healthcare settings globally. This interview took place at the 2026 European Society of Surgical Oncology (ESSO) Annual Meeting in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

No, but these vaccines, and I think it’s really important that because melanoma in Sweden is not a problem because we have, but in many countries, it’s actually a big problem that the primary tumour is gone somewhere and it’s not handled. And we have to build repositories, basically, and think that for every primary melanoma we remove, we have the kind of quality match that. So we have and the possibility to utilise it later on when patients maybe recur or needs to be treated adjuvantly at higher risks...

No, but these vaccines, and I think it’s really important that because melanoma in Sweden is not a problem because we have, but in many countries, it’s actually a big problem that the primary tumour is gone somewhere and it’s not handled. And we have to build repositories, basically, and think that for every primary melanoma we remove, we have the kind of quality match that. So we have and the possibility to utilise it later on when patients maybe recur or needs to be treated adjuvantly at higher risks. So it will definitely be. So surgeons are still needed and surgeons are very much needed in building up this multidisciplinary teamwork to make this feasible, because that is an interesting question with these new vaccines that we see. How will it be adopted and how will it actually in real world work? It’s one thing to do it in a very, what do you say, limited trial with all of the trial power you have in it. But to do within clinical reality throughout the world, it will be very interesting. And I think surgeons should be heavily involved in doing that as well.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.